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Abstract: Introduction. Our aim was to investigate the clinical features of primary new daily
persistent headache (NDPH) in a cohort of paediatric patients. Methods. We reviewed the data of
patients with persistent daily headache, attending the Headache Centre of Bambino Gesù Children
from the January 2009. The ICHD-III criteria were used for diagnosis. Statistical analysis was
conducted to study possible correlations between NDPH and population features (age and sex),
NDPH and headache qualitative features, and NDPH and response to pharmacological therapies.
Results. We included 46 subjects with NDPH. The features of pain more closely resembled those
of migraine than to those of tension-type headache (62 vs. 38%). The NDPH patients showed
nausea and vomiting less frequently than migraine ones (28.6 vs. 48.2%, p < 0.01). A total of 75% of
NDPH patients experienced an onset of the symptoms in the winter months (November to February)
(p < 0.01). NDPH was less common in very young children under 10 years of age. Almost 58% of
NDPH patients received pharmacological therapy and the most used drug was amitriptyline. A
reduction of attacks by at least 50% in a month was detected in 30.6% of patients. Conclusions. NDPH
can be very disabling and correlates with seasonal factors. Although long term pharmacological
therapy is recommended, considering the long duration that this headache can have, there are no
data supporting the treatment choice.
Keywords: new daily persistent headache; children; chronic headache; NDPH
1. Introduction
New Daily Persistent Headache (NDPH) consists of a persistent headache, daily from
its onset, which is clearly remembered [1]. NDPH prevalence ranges from 0.03 to 0.1% in
the general population and is higher in children and adolescents than in adults [2]. NDPH
accounts for 1.7 to 10.8% of children and adolescents with chronic daily headache [3].
NDPH is very often disabling and may significantly affect the individual’s quality of
life. It can even lead to psychiatric conditions [2,3]. The mechanisms that cause continuous
headache typical of NDPH are not well-understood. In the literature, there are clinical
studies conducted on the adult population that describe the characteristics of pain and
the presence of any trigger factors [2,3]. Far fewer are the paediatric pooling studies
with NDPH [4,5]. Furthermore, especially for what concerns the therapeutic management
of NDPH, to date, we have conclusive information. Although therapeutic controlled
drug trials are lacking, some authors [2] have suggested that NDPH should be treated
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according to the predominant headache phenotype; therefore, prophylactic drugs are
generally used for high-frequency migraine or tension-type headache. However, the need
for pharmacological treatment of NDPH at developmental age is quite debated considering
the existence of a self-limiting subtype that typically resolves within several months without
therapy [1].
The aim of this retrospective study was to describe the clinical features, trigger fac-
tors, and therapeutic options of NDPH in a paediatric cohort to better understand this
enigmatic disorder.
2. Materials and Methods
We retrospectively reviewed the charts of patients attending to the tertiary paediatric
medical Headache Center of Bambino Gesù Children’s Hospital. The electronic database
of the headache clinics was searched for all children and adolescents up to 18 years of
age, diagnosed with continuous primary headache with acute onset during the 2013 to
2019-time interval. To enter in the analysis, the main inclusion criteria was a persistent
headache, daily from its onset, and present for more than three months. Exclusion criteria
were a prior headache history, non-continuous remitting headache, secondary causes of
headache, the presence of other internist and/or neurological illness and/or head or neck
trauma, and the absence of a follow-up visit at least three months after the first observation.
Patients with a previous history of headache that could therefore be defined as chronic
migraine (CM) or chronic tension-type headache were excluded from the analysis. Trigemi-
nal autonomic cephalalgias (TACs) were excluded based on the absence of specific criteria
such as autonomic symptoms or response to indomethacin trial [1].
Secondary headaches were appropriately excluded in all patients through medical
history, physical examination (including fundus oculi examination), contrast-enhanced
magnetic resonance imaging (MRI), and, in some cases, lumbar puncture with cerebrospinal
fluid (CSF) pressure assessment. MRI was considered as a mandatory inclusion criterion.
A lack of lumbar puncture was not considered an exclusion criterion unless there were
clinical or neuroradiological elements suggesting a CSF pressure disorder (Figure 1). Sec-
ondary causes were identified in 11 patients with headaches resembling NDPH (23%)
and included idiopathic intracranial hypertension (4/60), Chiari 1 syndrome (2/60), and
brain tumors (5/60). In three patients eligible for the diagnosis of NDPH, the ICHD III
criteria for hemicrania continua were satisfied. In particular, in these patients, a trial with
indomethacin confirmed the diagnosis. The remaining 46 patients (12% of the whole CDH
population) received a definitive diagnosis of NDPH according to the ICHD-III criteria
(Figure 1). None of the definitive NDPH patients had a previous history of headache.




Figure 1. Subjects recruitment. sbj: subjects, IH: idiopathic intracranial hypertension, HC: hemicrania continua. 
Data on demographics, headache symptoms, and other clinical headache-related pa-
rameters were collected from the medical files of the patients who were found eligible to 
be included in the study. Electronic medical records included the following information: 
demographic data (age, sex), familiar medical history including headaches, pregnancy 
and birth history, past medical history, anthropometrical data (weight and height), gen-
eral physical exam and neurological exam including fundus oculi. Medical charts also in-
cluded the results of possible neuroimaging exams and the data from headache diaries. 
Headache diaries report the number of attacks per month, the duration of the attacks, 
qualitative features of pain, presence of associated symptoms (nausea, vomiting, phono-
phobia, and photophobia), intensity of pain, name of drug for the attack and response to 
therapy for the attack. Psychiatric scales were not systematically used in the assessment. 
Patients were divided into four age groups: 0–6, 7–10, 11–14, and 15–18 years. 
Clinical data concerning the duration and qualitative features of the headache at-
tacks, related symptoms, and pharmacologic therapies to induce remission were issued 
from the first and follow-up visits. These data were collected from interviews with chil-
dren and/or their parents. For very young children, the headache frequency and symp-
toms were determined by the child’s complaints and the parents’ impression from the 
child’s behaviour (according to the ICHD-III criteria) [1]. In addition, parents were ques-
tioned about possible medication overuse of their child. The medical interview was al-
ways followed by a complete full physical and neurological examination of the patient. 
As the NDPH criteria included a distinct and clearly remembered onset, with pain becom-
ing continuous and unremitting within 24 h (criterion B) [1], we looked for the possible 
presence of trigger factors in the headache history of the patients. Written informed con-
sent was obtained from the parents of the participants in this study. The study was ap-
proved by the Ethical Committee of Bambino Gesù Children’s Hospital. 
Statistical analysis was conducted by SPPS version 22.0 and ӽ2 test was used to verify 
the dependence between categorical variables. We tested in detail whether there was an 
association between: (a) NDPH frequency and age category or sex of patients, (b) NDPH 
and headache qualitative features (nausea, vomiting, phonophobia, and photophobia), 
and (c) the use of pharmacological therapy (amitriptyline, topiramate, flunarizine, and L-
5 hydroxytryptophan) and a reduction of at least 50% of the monthly days with a head-
ache. Furthermore, a multiple-regression logistic analysis has been used to evaluate 
whether age at first attack (0–6, 7–10, 11–14, 15–18 years), history of trigger or type of 
pharmacological treatment (topiramate, 5-hydroxytryptophan, flunarizine, amitriptyline) 
influenced the outcome (continuous headache for more than six months). The outcome 
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Data on demographics, headache symptoms, and other clinical headache-related
parameters were collected from the medical files of the patients who were found eligible to
be included in the study. Electronic medical records included the following information:
demographic data (age, sex), familiar medical history including headaches, pregnancy
and birth history, past medical history, anthropometrical data (weight and height), general
physical exam and neurological exam including fundus oculi. Medical charts also included
the results of possible neuroimaging exams and the data from headache diaries. Headache
diaries report the number of attacks per month, the duration of the attacks, qualitative
features of pain, presence of associated symptoms (nausea, vomiting, phonophobia, and
photophobia), intensity of pain, name of drug for the attack and response to therapy for
the attack. Psychiatric scales were not systematically used in the assessment.
Patients were divided into four age groups: 0–6, 7–10, 11–14, and 15–18 years.
Clinical data concerning the duration and qualitative features of the headache attacks,
related symptoms, and pharmacologic therapies to induce remission were issued from
the first and follow-up visits. These data were collected from interviews with children
and/or their parents. For very young children, the headache frequency and symptoms
were determined by the child’s complaints and the parents’ impression from the child’s
behaviour (according to the ICHD-III criteria) [1]. In addition, parents were questioned
about possible medication overuse of their child. The medical interview was always
followed by a complete full physical and neurological examination of the patient. As the
NDPH criteria included a distinct and clearly remembered onset, with pain becoming
continuous and unremitting within 24 h (criterion B) [1], we looked for the possible presence
of trigger factors in the headache history of the patients. Written informed consent was
obtained from the parents of the participants in this study. The study was approved by the
Ethical Committee of Bambino Gesù Children’s Hospital.
Statistical analysis was conducted by SPPS version 22.0 and χ2 test was used to verify
the dependence between categorical variables. We tested in detail whether there was an
association between: (a) NDPH frequency and age category or sex of patients, (b) NDPH
and headache qualitative features (nausea, vomiting, phonophobia, and photophobia),
and (c) the use of pharmacological therapy (amitriptyline, topiramate, flunarizine, and L-5
hydroxytryptophan) and a reduction of at least 50% of the monthly days with a headache.
Furthermore, a multiple-regression logistic analysis has been used to evaluate whether age
at first attack (0–6, 7–10, 11–14, 15–18 years), history of trigger or type of pharmacological
treatment (topiramate, 5-hydroxytryptophan, flunarizine, amitriptyline) influenced the
outcome (continuous headache for more than six months). The outcome was selected as a
dependent variable, and then all the other variables were tested as independent variables
in a block entry to evaluate the β standardized coefficient, the standard error (SE), the
significance and the upper and lower limit in a confidence interval (CI) of 95%.
A p-value of ≤0.05 was considered significant. A post-hoc correction for multiple
comparisons was made using the Bonferroni’s test, setting the significance cut-off at a/n
with α = 0.05 and final value of p = 0.01.
3. Results
3.1. Clinical Characteristics of NDPH Patients
According to the last version of ICHD, 60 patients (54% female and 46% male) had
an onset of headache suggestive of possible NDPH (Figure 1). The mean age of selected
patients was 13.4 years ± 3.2 standard deviation (SD) (range 5.3 to 17.9 years).
Among the NDPH patients, there was no difference between genders (55% females
and 45% males, p > 0.05). NDPH was less frequent under six years of age (8.7%) and above
14 years of age (19.6%) while a significant higher prevalence of NDPH was found in the
age groups between 7 and 10 years (28.3%) and between 11 and 14 years (43.5%) (p < 0.01).
Given the retrospective nature of this work we found that 15% of patients with possible
NDPH were initially diagnosed at the first medical visit as chronic migraine or chronic
tension-type headache. The reason for this was because a diagnosis was made solely based
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on the qualitative characteristics of the pain, without considering the de novo mode of the
onset of the headache.
3.2. Triggering Events
In 66% of NDPH cases, the onset of headache was correlated with the patient experi-
encing a temporally limited event, while in the remaining 34% of cases, neither the patient
nor his/her parents had memory of a triggering event.
Two types of triggering events were recognized: a stressful increase in school activities
was referred to in 46% of cases, while, according to 22% of cases, an infection of the upper
respiratory tract would have triggered headache. However, these conditions could not be
classified as secondary headaches, e.g., headache secondary to infections, because pain
persisted almost three months after the event (school-related stress and infection) was
over. Both trigger factors correlated with our finding of a far higher NDPH incidence in
the winter months, with a peak in January. During summer, a lower peak is recorded in
mid-June, coinciding with the end of the school year (Figure 2).
Diagnostics 2021, 11, x FOR PEER REVIEW 4 of 11 
 
 
was selected as a dependent variable, and then all the other variables were tested as inde-
pendent variables in a block entry to evaluate the β standardized coefficient, the standard 
error (SE), the significance and the upper and lower limit in a confidence interval (CI) of 
95%. 
A p-value of ≤0.05 was considered significant. A post-hoc correction for multiple 
comparisons was made using the Bonferroni’s test, setting the significance cut-off at a/n 
with α = 0.05 and final value of p = 0.01. 
3. Results 
3.1. Clinical Characteristics of NDPH Patients 
According to the last version of ICHD, 60 patients (54% female and 46% male) had 
an onset of headache suggestive of possible NDPH (Figure 1). The mean age of selected 
patients was 13.4 years ± 3.2 standard deviation (SD) (range 5.3 to 17.9 years). 
Among the NDPH patients, there was no difference between genders (55% females 
and 45% males, p > 0.05). NDPH was less frequent under six years of age (8.7%) and above 
14 years of age (19.6%) while a significant higher prevalence of NDPH was found in the 
age groups between 7 and 10 years (28.3%) and between 11 and 14 years (43.5%) (p < 0.01).  
Given the retrospective nature of this work we found that 15% of patients with pos-
sible NDPH were initially diagnosed at the first medical visit as chronic migraine or 
chronic tension-type headache. The reason for this was because a diagnosis was made 
solely based on the qualitative characteristics of the pain, without considering the de novo 
mode of the onset of the headache. 
3.2. Triggering Events 
In 66% of NDPH cases, the onset of headache was correlated with the patient experi-
encing a temporally limited event, while in the remaining 34% of cases, neither the patient 
nor his/her parents had memory of a triggering event. 
Two types of triggering events were recognized: a stressful increase in school activi-
ties was referred to in 46% of cases, while, according to 22% of cases, an infection of the 
upper respiratory tract would have triggered headache. However, these conditions could 
not be classified as secondary headaches, e.g., headache secondary to infections, because 
pain persisted almost three months after the event (school-related stress and infection) 
was over. Both trigger factors correlated with our finding of a far higher NDPH incidence 
in the winter months, with a peak in January. During summer, a lower peak is recorded 
in mid-June, coinciding with the end of the school year (Figure 2). 
 
Figure 2. Distribution of the onset of NDPH during the year. Figure 2. Distribution of the onset of NDPH during the year.
3.3. Qualitative Features and Associated Symptoms
The qualitative characteristics of pain reminded those of migraine in 73% of NDPH
patients and those of tension-type headache in 27% of cases. Pain location, quality, and
intensity are resumed in Table 1.
We found no statistically significant differences between males and females. Regarding
the various age groups, the only difference was in the intensity of the pain which was more
frequently mild in patients under the age of six years (75%) than in the other age groups
(47% for 7–10 years; 42% for 11–15 years and 38% for 15–18).
Patients with chronic migraine (247/369 patients) were then compared with those
with NDPH (46/369) to verify if there were differences in the associated sensorial and
vegetative symptoms. We did not find a statistically significant difference between the
proportion of patients who experience and do not experience photophobia and phono-
phobia between the group of CM (25% without photophobia, 74.5% with photophobia,
20.8% without phonophobia, and 79.2% with phonophobia; p > 0.05) and NDPH (20.8%
without photophobia, 79.2% with photophobia, 37% without phonophobia, and 63% with
phonophobia; p > 0.05) (Figure 3).
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Table 1. Location, quality, and intensity of pain in paediatric patients with NDPH.
Location of pain
Frontal 16/46 pts (35%)
Occipital 2/46 pts (4%)
Whole hemisphere 10/46 pts (21%)
Monolateral 28/46 pts (61%)
Bilateral 18/46 pts (39 %)
Intensity of pain
Mild 11/46 pts (24%)
Moderate 23/46 pts (50%)
Severe 12/46 pts (26%)
Pain Quality
Throbbing 19/46 pts (41%)
Gravative 7/46 pts (15%)
Pressing 13/46 pts (28%)
Other quality 4/46 pts (9%)
Not determined 3/46 pts (7%)
pts: patients.
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Regarding vegetative symptoms, NDPH patients experienced nausea and vomiting
less often than CM patients (28.3% vs. 58%; p < 0.01).
3.4. Treatment
Data concerning the use of pharmacological therapy aimed to induce remission of
pain were issued to 33 patients (67%). The remaining 16 patients (33%) did not undergo
preventive drug treatment. In particular, 10 patients did not receive any preventive therapy,
while the remaining six patients were treated with non-pharmacological therapies (three
patients underwent nutraceutics, two underwent psychotherapy, and one acupuncture).
The main reasons for the lack of drug therapy were the mild intensity of the attacks, the
interference with school and extracurricular activities, and the refusal of drugs by parents.
The drugs used included flunarizine (5 mg/die) (3.7%), topiramate (1–2 mg/kg/die)
(14.8%), and amitriptyline (1 mg/kg/die) (92.3%).
Almost 80% of patients had a beneficial response (reduction in the frequency of attacks
by at least 50%), while 20% of patients showed no improvement. We found that 35% of
patients did not have a response to the attack drugs (nonsteroidal anti-inflammatory drugs
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or triptans). Only one patient had a concomitant history of medication overuse headache
(MOH); after correcting the excessive use of drugs for the attack, we did not observe a
change in the frequency of the headache.
3.5. Outcome
As for the outcome, the average duration of continuous daily pain from the onset was
8.4 ± 2 months. We observed also that 43% of patients had continuous pain resolution
within six months, 39% within 12 months, and 18% kept referring to continuous pain
after 12 months. After a mean follow-up period of 22 ± 5 months, we observed that, over
time, 54% of the NDPH population returned to a remitting form of headache (complete
remission or frequency of attacks less than five days per month), 35% a had history of
relapsing remitting headache (periods of continuous daily headache alternating with
pain-free periods), and 11% continued to have persistent headache from the onset.
Unfavourable outcome (persistence of pain after six months) predictors were no
history of a trigger event (β 3.5; SD 1.0; CI 0.6–4.6) and no pharmacological treatment (β 2.6;
SD 1.5; CI 0.3–5.1).
4. Discussion
The recent study showed that, in NDPH patients, characteristics of pain and associated
symptoms more closely resembled those of migraine than to those of tension-type headache.
Triggers identified by patients and their families included stressful school activities or
infectious events. The duration of the NDPH could persist for six months or more, and the
worst outcome was associated with the absence of identifiable trigger factors and a lack of
pharmacological therapy.
Moreover, this study underlines how some aspects of the ICHD-III diagnostic criteria
need to be clarified in order to help the diagnosis of NDPH in developmental-age patients.
In the ICHD-III criteria, no reference is made to the specific qualitative characteristics
of pain or the presence of associated symptoms to make the diagnosis of NDPH [1]. In
our cohort, 73% of patients reported headache characteristics similar to those of migraine.
This is consistent with prior studies showing that paediatric patients with NDPH have
a migrainous phenotype of their headache [4]. However, when compared to patients
with chronic migraine, our NDPH patients were less often referred with nausea and
vomiting. Recently, a large study conducted on 1170 young people (ages 3 to 17) with
continuous headache analyzed the main differences between CM and NDPH in paediatric-
age patients [5]. Paediatric patients with NDPH compared to CM patients generally
experienced onset at a later age, less often presenting with photophobia, and less frequently
developing an MOH [5].
These studies, as well as ours, show that although the characteristics of pain resemble
those of migraine, there are elements of distinction. Furthermore, we agree that what most
characterizes NDPH and differentiates it from other chronic headaches is more the modality
of onset than the characteristics of pain. This also makes it possible to distinguish patients
with NDPH from patients with migraine or tension-type headache whose headaches have
begun to change from episodic to chronic. None of our patients with NDPH had a previous
history of headache.
Another important finding is that the role of trigger factors in NDPH should be more
emphasized even at paediatric age. Patients with NDPH often have a very distinct memory
of the onset of the headache and can relate it to a trigger event [1]. Trigger factors described
in adults are very different from those in children with NDPH. Studies on adults have
reported surgery, dental extractions, electric shock, anaesthesia, infections, psychological
stress (work, family, or financial problems), lifestyle changes, or moderate trauma as
being among the most frequent events [5,6]. Other reported precipitating factors include
withdrawal from SSRIs, human papilloma virus vaccination, menarche and postpartum
state, hormone manipulation with progesterone, toxin and medication exposure, cervical
massage treatment, simple syncopal attack, and thyroid diseases [1,7].
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An important datum is that some authors have pointed out that patients are often
unaware of situations that can trigger headaches [8]. In the suspicion of NDPH it is
therefore very important, when collecting the anamnesis, to question the patient about
trigger events that have preceded the onset of pain.
In a study of 40 paediatric headache patients with NDPH, precipitating events were
noted in 88% of cases: febrile illness in 43%, preceding minor head injury in 23%, and
cranial or extra cranial surgery in 10% [9]. Moreover, at paediatric age, chronic headaches
often show a seasonal cyclical pattern, which has been related to school activities [10–12]. In
paediatric NDPH, the hypothesis has been made that the onset can fall in the months when
children start or return to school [4,11,13]. In our NDPH patients, stressful school activity
was a frequently recognized trigger event (46% of patients). Indeed, a significant increase
in NDPH onset was found in the months when students started school after summer break
(September) or returned to school after winter break (January) (Figure 2).
The second most frequent trigger identified in our patients was represented by flu-like
infectious episodes (22% of patients). In two previous case series [9,14], an episode of flu
or a “cold” preceded NDPH onset in 30 and 42% of patients, respectively. NDPH was
associated with other infective agents, such as herpes simplex virus, cytomegalovirus,
salmonella, adenovirus, toxoplasma, and herpes zoster [15]. Given the variety of infectious
associations, it has been suggested that the nonspecific inflammatory response initiated
by the infection, rather than the infectious agent itself, may be the trigger [16]. None of
these studies discuss whether, in the presence of a precipitating event, the diagnosis of
NDPH can be maintained or not. It is in fact necessary to distinguish when a headache is
caused by a systemic infection from when the headache is triggered by a systemic infection.
According to ICHD-III (part 2, paragraph 9) when a new headache occurs for the first time
in close temporal relation to an infection, it is coded as a secondary headache attributed to
that infection [1].
When a pre-existing headache with the characteristics of a primary headache disorder
becomes chronic or is made significantly worse (usually meaning a two-fold or greater
increase in frequency and/or severity), in close temporal relation to an infection, both the
initial primary headache diagnosis and a diagnosis of headache attributed to infection
should be given, provided that there is good evidence that the disorder can cause headache.
For headache attributed to infection, the evidence of causation should be demonstrated [1].
Headache attributed to infection is usually the consequence of active infection, resolving
(acute) or not (chronic) within three months of eradication of the infection. Otherwise,
NDPH triggered by an infection instead refers to a headache that persists beyond three
months without evidence of another cause including an infection. We believe that the ICHD-
III criteria should specify that when the headache persists for more than three months,
the persistence of the infection must be demonstrated in order to differentiate a chronic
infection headache from an NDPH. In our case history, only those who had a headache for
more than three months with an infection resolved before were considered NDPH.
Regarding the diagnostic workout, we know that in the notes of version 3 of the ICHD,
experts in particular ask to exclude other forms of headache that could mimic NDPH,
for example, arteriovenous malformation, brain tumors, cerebral venous thrombosis, and
chronic subdural hematoma (Table 2).
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Table 2. Differential diagnosis of NDPH.
Item Presence of: Consider Other Conditions:
Headache History
Previous history of primary
headache
Absence of trigger factor
Worsening of primary headache
Excessive use of drugs for the
attacks Considering MOH
Head or neck trauma Headache secondary to trauma
Worsening with Valsalva, or
changes in posture Altered CSF pressure
Pain lasting 15 to 180 min Cluster headache
Pain lasting 2 to 30 min Paroxysmal hemicrania
Neurological Exam Focal signAltered consciousness
Secondary cause of headache
(i.e., vascular disorders, altered
CSF pressure, neoplasia, CNS
infections)
General examination








Other secondary causes of
headache.
Drug Response Indomethacin * Hemicrania Continua
MOH: Medication Overuse Headache; CSN: central nervous system; TACs: Trigeminal Autonomic Cephalalgias;
CSF: Cerebrospinal fluid. * The indomethacin dosage necessary for successful treatment ranges from 25 to 300 mg
per day, with an average of 100 mg per day. The beneficial effects appear within two days (range, one to five
days). On discontinuation, headache reappears in about three days (range, 1 to 14 days).
In our cases, secondary forms of headache have been identified in 23% of patients
with headache onset, suggestive for possible NDPH. All patients with secondary forms
had neuroimaging or fundus oculi alterations that suggested the presence of a brain tumor,
Chiari malformation type 1, or idiopathic intracranial hypertension (IIP).
Finally, all patients with possible NDPH carried out a trial with indomethacin with a
response in three patients who consequently received a diagnosis of HC.
The clinical history of the headache, the neurological and fundus examination to-
gether with the drug history and a neuroradiological study are essential in the differential
diagnosis of NDPH. Regarding the need to perform the lumbar puncture, we could raise
some questions. The ICHD 2 version for the diagnosis of NDPH did not require the lumbar
puncture to confirm the diagnosis of NDPH through the exclusion of alterations in the
CSF pressure. The third version of ICHD includes in the notes the need to exclude in all
cases of possible NDPH other headaches attributed to increased or low cerebrospinal fluid
pressure. In paediatric-age patients, however, performing lumbar puncture is not always
an easy procedure as it is for adults and often also requires sedation. For this reason, in our
retrospective analysis, this invasive procedure was performed only in patients for whom
the neurological examination or neuroimaging showed indirect signs of IIP. Patients with
clinical history typical for NDPH, without papilledema and without neuroradiological
alterations had not been subjected to lumbar puncture. Finally, no patients diagnosed with
NDPH changed their diagnosis during follow up or developed other symptoms or signs
suggestive of an alteration in CSF pressure over the time period studied. These points on
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the need to perform a lumbar puncture for the confirmation of NDPH should therefore
be clarified.
About the outcome of patients with NDPH, we found that, in our patients, the average
duration of continuous daily pain was about 8.4 ± 2 months; 43% of patients had contin-
uous pain resolution within six months, 39% within 12 months and 18% kept suffering
from continuous pain beyond 12 months. Patients who did not receive pharmacological
therapy were at greater risk of having a worse prognosis—in particular, the persistence
of NDPH after 12 months. Another negative prognostic indicator was the absence of a
well-recognized trigger factor.
Studies in paediatric [17,18] and adult [19–23] NDPH patients often reached conflicting
results concerning the outcome. While, according to some studies, NDPH does not interfere
with the subject’s activities and its resolution is spontaneous within 24 months [22,23],
others emphasize its disabling trend, drug resistance and poor prognosis [19–21].
NDPH treatments is usually a challenge. Although there are no prospective placebo-
controlled trials for NDPH pharmacological treatment, the same preventive medications
indicated for chronic tension-type headache or chronic migraine, including tricyclic an-
tidepressants (amitriptyline) and antiepileptics (topiramate, valproic acid, gabapentin),
are commonly used [18]. Botulinum toxin proved useful for the treatment of NDPH in
adults, while no evidence is available for childhood cases [24]. Muscle relaxants, such
as baclofen or tizanidine, may be helpful [20]. There are very scattered data concerning
only adult populations about the use of corticosteroids [25], lidocaine [26], nimodipine [8],
and ketamine [27] in NDPH. For some patients, headache escalations may respond to
triptans [6]. In our series, 35% of patients did not have a response to the symptomatic
drugs (NSAIDs or triptans). Regarding pharmacological treatment, around 80% of patients
had a beneficial response (reduction in the frequency of attacks by at least 50%), while 20%
of patients showed no improvement. The most-used drugs included flunarizine (5 mg/die)
(3.7%), topiramate (1–2 mg/kg/die) (14.8%), and amitriptyline (1 mg/kg/die) (92.3%).
We often chose amitriptyline for its available evidence of efficacy in chronic paediatric
headaches [28].
Although the difficulty in finding effective therapies could lead to the development of
MOH, there is no evidence of a correlation between MOH and NDPH in paediatric-age
patients. Interestingly, for one of our patients, who had a concomitant history of MOH, the
withdrawal of the overused drugs did not improve headache. In light of these data, and
considering that even the self-limiting forms of NDPH can be disabling, we suggest trying
a pharmacological approach.
Limitations of the Study
The main limitation of this study is the retrospective nature of the data collection.
It is not possible to draw definitive conclusions on the efficacy of traditional drugs for
the prophylaxis of migraine, as a comparison with a control group is not foreseen and the
analysis is not longitudinal.
Not all of our patients then performed the lumbar puncture as indicated in the notes
of the ICHD-III.
However, the number of patients recruited considering the paediatric age is not low,
and our results offer the opportunity to extend the studies on the mechanisms of the onset
of NDPH, what affects the different outcomes, and what may be the best treatment strategy.
5. Conclusions
NDPH represents a challenge to neuropediatricians in terms of both its diagnosis and
therapy. A correct diagnosis with the exclusion of secondary causes and other chronic
forms of primary headache is mandatory. Patients should be questioned about the mode of
onset and the presence of trigger factors. The ICHD-III criteria should specify that when
the headache persists for more than three months, the persistence of the infection must also
be demonstrated in order to differentiate a chronic infection headache from an NDPH.
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NDPH can last several months and be extremely disabling for the patient. Therefore,
pharmaceutical treatment should be attempted, in spite of the lack of standardized guide-
lines for the use of drugs. In our patients, starting a treatment was associated with a more
favourable outcome.
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